3647 results for «604»
3647 results
Atypical STEMI presentations
20 May 2026 – From EuroPCR 2026
Investigate atypical presentations of STEMI and the unique challenges they pose in clinical management. This session covers case studies including high bleeding risk patients, mechanical complications post-surgery, spontaneous coronary artery dissection, and recurrent events, emphasizing tailored therapeutic approaches.
TTVR: novel techniques and new horizons
20 May 2026 – From EuroPCR 2026
Explore novel techniques and emerging technologies in transcatheter tricuspid valve replacement (TTVR). This session showcases innovative devices and approaches, early clinical experiences, and strategies to address challenges such as pacemaker leads and failed tricuspid TEER procedures.
Mitral valve-in-valve, valve-in-ring, valve-in-mac: the good, the bad and the ugly
20 May 2026 – From EuroPCR 2026
This session delves into the complexities of mitral valve interventions, focusing on valve-in-valve, valve-in-ring, and valve-in-mitral annular calcification (MAC) procedures. It addresses troubleshooting in high-risk valve-in-MAC cases, urgent transcatheter mitral valve implantation supported by microaxial flow pumps, challenges in delivering balloon expandable valves transeptally, and innovative...
Cardiogenic shock: identifying the cause and tailoring the treatment
20 May 2026 – From EuroPCR 2026
This session focuses on the critical evaluation and management of cardiogenic shock by identifying its underlying causes and tailoring treatment accordingly. It presents complex cases including free wall rupture bail-out strategies, management dilemmas in inferior STEMI complicated by incomplete ventricular rupture, multifactorial culprit lesions, refractory hypotension...
Which AF patients may benefit from LAA closure?
02 Jul 2026
Martin Bergmann reviews the evolving evidence for LAAC, examining how recent landmark trials such as OPTION, CLOSURE‑AF and CHAMPION‑AF are reshaping patient selection and expanding the role of LAAC across a broader spectrum of patients with atrial fibrillation.

Author
Drug-coated balloon (DCB) technology: A pioneer’s view of the historical evolution and future directions
08 Jan 2025
In this article, Bruno Scheller explores advances in local drug delivery, from drug-coated balloons to novel antiproliferative agents. These innovations aim to reduce restenosis, minimize permanent implants, and pave the way for patient-specific coronary artery disease treatments.

Author
Future directions of drug-coated balloon angioplasty
06 Feb 2025
Fernando Alfonso and Javier Cuesta discuss the growing role of drug-coated balloons as an alternative to stents in percutaneous coronary interventions. Highlighting advantages like reduced in-stent restenosis, they emphasize the need for robust clinical studies to refine DCB use.

Author

Author